Kymera Therapeutics, Inc.
KYMR NASDAQHealthcare ★★★★★Latest Earnings
Date
Aug 5, 2026
ET
EPS Est.
-0.71
EPS Actual
-0.62
Revenue Est.
$32.8M
Revenue Actual
$65M
Next Earnings Report
Date
Nov 3, 2026 · Tue
Time
Pre-market
Fiscal Period
FY2026 Q3
EPS Est.
-1.23
Revenue Est.
$3.8M
Company Overview
Kymera Therapeutics, Inc. (ticker KYMR) is listed on NASDAQ with a market cap of about $9.85B. Its next earnings report (FY2026 Q3) is expected on Nov 3, 2026 (ET), Pre-market, with consensus EPS of -1.23. In the last 15 reported quarters, EPS beat consensus estimates 8 times.
Actual EPS TrendRecently15Term · Feb 23, 2023 → Aug 5, 2026
Feb 23, 2023Range: -0.97 ~ -0.25Aug 5, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Aug 5, 2026 | -- | -0.71 | -0.62 | $32.8M | $65M |
| Apr 30, 2026 | -- | -0.89 | Above forecast↑-0.71 | $8.3M | $34.4M |
| Feb 26, 2026 | -- | -0.78 | Below forecast↓-0.97 | $15M | $2.9M |
| Nov 4, 2025 | -- | -0.71 | Below forecast↓-0.90 | $14.5M | $2.8M |
| Aug 11, 2025 | -- | -0.83 | -0.95 | $17.1M | $11.5M |
| May 9, 2025 | -- | -0.92 | -0.82 | $12.4M | $22.1M |
| Feb 27, 2025 | -- | -0.76 | Below forecast↓-0.88 | $16.7M | $7.4M |
| Oct 31, 2024 | -- | -0.83 | -0.82 | $15.2M | $3.7M |
| Aug 7, 2024 | -- | -0.69 | Above forecast↑-0.58 | $12.6M | $25.7M |
| May 2, 2024 | -- | -0.73 | -0.69 | $13.7M | $10.3M |
| Feb 22, 2024 | -- | -0.44 | Above forecast↑-0.25 | $42M | $47.9M |
| Nov 2, 2023 | -- | -0.73 | Below forecast↓-0.90 | $16M | $4.7M |
| Aug 3, 2023 | -- | -0.70 | -0.67 | $14.1M | $16.5M |
| May 4, 2023 | -- | -0.69 | -0.70 | $14.2M | $9.5M |
| Feb 23, 2023 | -- | -0.57 | -0.60 | $22.1M | $16.1M |
Original Filings (SEC)
10-Q2026-08-05 ↗
8-K2026-08-05 ↗
8-K2026-07-27 ↗
8-K2026-06-25 ↗
8-K2026-06-24 ↗
8-K2026-06-08 ↗
10-Q2026-04-30 ↗
8-K2026-04-30 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
